Financials data is unavailable for this security.
View more
Year on year Spero Therapeutics Inc grew revenues 93.95% from 53.51m to 103.78m while net income improved from a loss of 46.42m to a gain of 22.81m.
Gross margin | -- |
---|---|
Net profit margin | 14.74% |
Operating margin | 13.13% |
Return on assets | 14.03% |
---|---|
Return on equity | 25.81% |
Return on investment | 18.79% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Spero Therapeutics Inc fell by 32.77m. Cash Flow from Financing totalled 221.00k or 0.21% of revenues. In addition the company used 33.00m for operations while cash from investing was breakeven.
Cash flow per share | 0.3291 |
---|---|
Price/Cash flow per share | 4.05 |
Book value per share | 1.49 |
---|---|
Tangible book value per share | 1.49 |
More ▼
Balance sheet in USDView more
Current ratio | 2.68 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼